436 related articles for article (PubMed ID: 17218256)
21. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
Levaot N; Voytyuk O; Dimitriou I; Sircoulomb F; Chandrakumar A; Deckert M; Krzyzanowski PM; Scotter A; Gu S; Janmohamed S; Cong F; Simoncic PD; Ueki Y; La Rose J; Rottapel R
Cell; 2011 Dec; 147(6):1324-39. PubMed ID: 22153076
[TBL] [Abstract][Full Text] [Related]
22. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
23. Chloroform extract of deer antler inhibits osteoclast differentiation and bone resorption.
Li YJ; Kim TH; Kwak HB; Lee ZH; Lee SY; Jhon GJ
J Ethnopharmacol; 2007 Sep; 113(2):191-8. PubMed ID: 17646068
[TBL] [Abstract][Full Text] [Related]
24. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
25. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
26. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
27. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.
Komano Y; Nanki T; Hayashida K; Taniguchi K; Miyasaka N
Arthritis Res Ther; 2006; 8(5):R152. PubMed ID: 16987426
[TBL] [Abstract][Full Text] [Related]
28. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
[TBL] [Abstract][Full Text] [Related]
29. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
[TBL] [Abstract][Full Text] [Related]
30. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta.
Lari R; Fleetwood AJ; Kitchener PD; Cook AD; Pavasovic D; Hertzog PJ; Hamilton JA
Bone; 2007 Feb; 40(2):323-36. PubMed ID: 17055352
[TBL] [Abstract][Full Text] [Related]
31. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
[TBL] [Abstract][Full Text] [Related]
32. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
33. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
34. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis.
Fujita S; Mukai T; Mito T; Kodama S; Nagasu A; Kittaka M; Sone T; Ueki Y; Morita Y
Bone; 2018 Jan; 106():156-166. PubMed ID: 29055830
[TBL] [Abstract][Full Text] [Related]
36. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
37. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
38. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
39. PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts.
Chitu V; Nacu V; Charles JF; Henne WM; McMahon HT; Nandi S; Ketchum H; Harris R; Nakamura MC; Stanley ER
Blood; 2012 Oct; 120(15):3126-35. PubMed ID: 22923495
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow monocyte PECAM-1 deficiency elicits increased osteoclastogenesis resulting in trabecular bone loss.
Wu Y; Tworkoski K; Michaud M; Madri JA
J Immunol; 2009 Mar; 182(5):2672-9. PubMed ID: 19234161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
